Lupus Therapeutics Partners with Takeda on Phase 1 Trial

NEW YORK, March 1, 2019 /PRNewswire/ --The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial ( NCT03724916 ).